HAVCR2 and acute myeloid leukemia: Herein, we first introduced the third-generation CAR to target TIM3, which is highly expressed in primitive LSCs and LPCs, into human iPSCs to subsequently produce CAR-TIM3 NK-like cells in order to eradicate the root cause of relapsed/refractory AML.